Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Latest filing published 30 Jun 2025 for Actuate Therapeutics, INC., €428k. Read the official filing
Filing timeline
BuySaleBios Equity COF, LP
Insider track record
Disclosed buys
1
Disclosed sells
1
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -76.5%Entry US$6.13 · Close at T+365 US$1.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Bios Equity COF, LP: trading record in brief
Bios Equity COF, LP discloses dealings in Actuate Therapeutics, Inc. to SEC (Form 4). Between 14 August 2024 and 27 June 2025, the trades on record add up to 3 filings.
The open-market side counts 1 purchase for €428k alongside 1 sale for €39k. Taken together, the purchases exceed the sales by €389k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2025 alone, the filings show 1 purchase and no sales.
The record was last updated on 30 June 2025 with an open-market purchase (€428k) in Actuate Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Bios Equity COF, LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
71,428 shares@ US$7.001.96% mcap91.7% of flowCommon StockSEC:0001104659-25-063993:0
Canonical exit: 25 Sept 2025 (T+90)
▼
Same trade as the filing by Aaron G.L. Fletcher, counted once · View ↗
5,314 shares@ US$8.008.3% of flowCommon StockSEC:0001104659-24-091372:0
884,427 sharesCommon StockSEC:0001104659-24-089825:0
3 of 2 declarations
